Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Johnson & Johnson — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $19.08 (market cap $370.88M), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 1666.5× YieldMax COIN Option Income Strategy ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while YieldMax COIN Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax COIN Option Income Strategy ETF for 41 Days and Johnson & Johnson for 129 Days on average.
| CONY | JNJ | |
|---|---|---|
Market Cap | $370.88M | $618.09B |
Volume | 595,904 | 6,050,983 |
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $278.43 |
52-Week Low | $17.73 | $186.00 |
Typical Hold Time | 41 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.04, down 0.63% on the day, with a bearish technical signal from moving averages but bullish oscillators like RSI indicating potential oversold conditions. The ETF has experienced significant price erosion year-to-date, with a 51.3% decline noted in recent analysis, despite offering high distribution yields. Recent news highlights weekly dividend announcements and regulatory impacts on crypto-related stocks.
The outlook remains challenging due to structural NAV decay and full downside exposure to COIN. While the shift to a call spread strategy offers partial upside participation, the fund's high-risk profile and regulatory uncertainties present substantial headwinds for investors seeking stable returns.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
